Gallstones don’t need to be obvious to be dangerous. Catching them early can help prevent serious complications ...

Compared with the use of SGLT2 inhibitors, the use of GLP-1 receptor agonists and DPP-4 inhibitors was associated with a similar risk for acute pancreatitis (hazard ratio [HR], 1.01; 95% CI, 0.90-1.13 ...

New evidence shows that colic is usually a benign gut–brain interaction disorder, and only infants with additional allergic symptoms should undergo a structured cow’s-milk elimination and ...

In response to high cholesterol or an unhealthy diet, your gallbladder may produce hardened pieces of cholesterol and pigment called gallstones. You might wonder what this means for your health. In ...

TUPELO – Dr. Will Cauthen doesn't have to crunch numbers in his head when speaking of the gallbladder surgeries he's performed. He does between 200 to 250 a year. Gallstones are the culprit in causing ...

Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Primary biliary cholangitis (PBC) is an autoimmune disease that causes the destruction of bile ducts within the liver. The loss of bile ducts results in bile acid buildup, which causes inflammation ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Ahmad Anouti, MD, about a presentation at The Liver Meeting on the prognostic value of ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or ...